Japan Allergy Therapeutics Market Analysis

Japan Allergy Therapeutics Market Executive Summary

Japan Allergy Therapeutics Market was valued at $1442 Mn in 2022 and is estimated to reach $2459 Mn in 2030, exhibiting a CAGR of 6.9% during the forecast period.

Allergies are immune responses that are periodically triggered by environmental chemicals known as allergens. Dust mites, pollen, mildew, and specific foods like milk, eggs, soy, and almonds are examples of common allergies. Allergy reactions can manifest in a variety of ways, ranging from mild symptoms like runny nose and itchy eyes to more serious ones like anaphylaxis, which can cause unconsciousness and breathing problems. A few potential treatment options include immunotherapy, avoiding allergens, and prescription medications such antihistamines and nasal corticosteroids.

Significantly, 62.2% of Japanese people suffer from an allergic illness. Approximately 47.4% of the population suffers from allergic rhinitis (AR), a condition that is more common in males and children. The symptoms of allergic rhinitis include runny nose, itchy eyes, congestion, and sneezing. About 14.7% of people have asthma, which is more common in boys and children. The illness causes coughing, chest tightness, wheezing, and shortness of breath. About 15.6% of people have atopic dermatitis, with prevalence greater in women and adults. The condition is characterized by symptoms such as dry, itchy, and inflammatory skin.

An innovative anti-IL-31 receptor antibody called MT8856 is being developed by Mitsubishi Tanabe Pharma Corporation with the goal of treating severe atopic dermatitis and persistent spontaneous urticaria. In order to avoid peanut allergies, Chugai Pharmaceutical Co., Ltd. is leading the way in research on nimotuzumab, a humanized anti-FcεRI monoclonal antibody. Additionally, Kyowa Kirin Co., Ltd. is advancing clinical studies for KSK39251, a small-molecule oral JAK inhibitor, as a potential treatment for severe atopic dermatitis.

Market Dynamics

Market Growth Drivers

Prevalence of Allergies: The rising incidence of respiratory allergies and other allergic illnesses, such as hay fever, is creating a need for effective allergy therapy drugs. Urbanization, changes in lifestyle, and environmental factors may all contribute to an increase in the prevalence of allergies.

Advancements in Allergen Immunotherapy (AIT): Sublingual immunotherapy (SLIT) patches and pills are examples of innovative replacements that have been developed, and they may provide longer-lasting relief with fewer side effects. This creates new business opportunities for these cutting-edge treatments.

Increased Awareness and Diagnosis: More access to healthcare, public health campaigns, and educational programs result in earlier and more accurate allergy diagnoses, which encourage people to seek treatment.

Market Restraints

High Cost of Treatment: The cost of allergy treatment can be very prohibitive for some people, particularly when it comes to AIT procedures like immunotherapy injections and SLIT tablets. The high price of allergy medications may prevent them from being widely used and made accessible, which would limit their market penetration.

Treatment Compliance and Adherence: Consistent commitment to long-term regimens is crucial for the efficacy of allergy treatments, especially immunotherapy therapies. Obstacles including exorbitant expenses, complexity, or unfavourable outcomes resulting in insufficient patient compliance possess the capacity to reduce therapy effectiveness and hinder the market's growth.

Cultural and Behavioural Factors: Market penetration may be hampered by certain groups preference for traditional medications or home cures over contemporary treatments. Decreased public awareness could make it harder to identify and comprehend allergy symptoms, which could cause a delay in diagnosis and treatment. Despite these drawbacks, using non-pharmaceutical methods like air filters to lower allergens and/or get rid of allergy symptoms is growing in popularity.

Healthcare Policies and Regulatory Landscape

The primary regulatory body in charge of assessing and approving allergy treatment medications and guaranteeing compliance with strict safety and efficacy standards is the Pharmaceuticals and Medical Devices Agency (PMDA). Collaborating with the PMDA, the Ministry of Health, Labour and Welfare (MHLW) influences recommendations pertaining to drug safety and accessibility and helps formulate broad healthcare policy. In the areas of allergy research, treatment recommendations, and more general healthcare advocacy, professional associations like the Japan Medical Association (JMA) and the Japan Society of Allergology (JSA) may be involved. Reimbursement decisions are influenced by the National Health Insurance (NHI) System, which is managed by local governments. This has an effect on how affordable and accessible allergy treatments are for patients throughout Japan.

Competitive Landscape

Key Players

• Eisai Co.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Sanofi
• GlaxoSmithKline (GSK)
• AstraZeneca
• Mitsubishi Tanabe Pharma Corporation
• Shionogi & Co.,
• Kowa Pharmaceutical Co.
• Daiichi Sankyo Co.